比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌患者的疗效观察

Effect of Bikalumide Combined with Goserelin in Patients with Advanced Prostate Cancer

【目的】 探讨比卡鲁胺治疗晚期前列腺癌患者的临床疗效。【方法】 选取2016年1月至2017年12月本院诊治的晚期前列腺癌患者92例,按照随机数表法分为观察组和对照组,每组46例。对照组采用戈舍瑞林常规治疗,观察组在常规治疗的基础上加用比卡鲁胺治疗,比较两组患者治疗后的临床疗效及治疗前后血清前列腺特异性抗原(PSA)、血管内皮生长因子(VEGF)、miRNA-34a(miR-34a)、胰岛素样生长因子-1(IGF-1)水平、SMYD3表达阳性率、生命质量测定量表(QLQ-C30)评分及患者满意度。【结果】 观察组总有效率为95.65%(44/46),显著高于对照组的80.43%(37/46),其差异有统计学意义(P<0.05)。两组患者治疗前PSA、VEGF、miR-34a、胰岛素样生长因子-1(IGF-1)水平、SMYD3表达阳性率、生命质量测定量表(QLQ-C30)评分比较差异无统计学意义(P>0.05);治疗后,观察组患者PSA、VEGF、IGF-1水平及SMYD3表达阳性率低于对照组,miR-34a水平、QLQ-C30评分高于对照组(P<0.05)。观察组患者满意度为95.65%,显著高于对照组的54.35%,其差异有统计学意义(P<0.05)。【结论】 比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌患者疗效显著,可降低PSA、VEGF、IGF-1水平,提高miR-34a水平,有效控制SMYD3表达,改善患者生活质量,提高患者满意度。

【Objective】 To investigate the efficacy of bikalumide in patients with advanced prostate cancer.【Methods】 A total of 92 patients with advanced prostate cancer admitted in our hospital from January 2016 to December 2017 were randomly divided into two groups, with 46 cases in each group. Patients in the control group received routine therapy with foserelin, while patients in the observation group was treated with bikalumide on the basis of foserelin routine treatment. The clinical efficacy and serum prostate specific antigen (PSA), vascular endothelial growth factor (VEGF), miRNA-34a (miR-34a), insulin-like growth factor-1 (IGF-1) levels and SMYD3 positive expression rate were compared before and after treatment. Quality of life measurement scale (QLQ-C30) score and patient satisfaction were evaluated as well.【Results】 The total effective rate of the observation group was 95.65% (44/46), which was significantly higher than that of the control group (80.43% (37/46)). The difference was statistically significant (P<0.05). There were no statistically significant differences between the two groups in the levels of PSA, VEGF, miR-34a,IGF-1, SMYD3 and QLQ-C30 before treatment (P>0.05). After treatment, the levels of PSA, VEGF, IGF- and SMYD3 in the observation group were lower than those in the control group, and the level of miR-34a and QLQ-C30 score were higher than those in the control group (P<0.05). The patient satisfaction in the observation group was 95.65%, which was significantly higher than that in the control group 54.35%, and the difference was statistically significant (P<0.05). 【Conclusion】 Bikalumide combined with goserelin have significant therapeutic effect in patients with advanced prostate cancer, which can reduce levels of PSA VEGF and IGF-1, increase miR-34a level, effectively control SMYD3 expression, improve the quality of life and enhance patient satisfaction.